Skip to main content

Advertisement

Log in

Human mesenchymal stem cell secretomes: Factors affecting profiling and challenges in clinical application

  • Review
  • Published:
Cell and Tissue Research Aims and scope Submit manuscript

Abstract

The promising field of regenerative medicine is thrilling as it can repair and restore organs for various debilitating diseases. Mesenchymal stem cells are one of the main components in regenerative medicine that work through the release of secretomes. By adopting the use of the secretome in cell-free-based therapy, we may be able to address the challenges faced in cell-based therapy. As one of the components of cell-free-based therapy, secretome has the advantage of a better safety and efficacy profile than mesenchymal stem cells. However, secretome has its challenges that need to be addressed, such as its bioprocessing methods that may impact the secretome content and its mechanisms of action in clinical settings. Effective and standardization of bioprocessing protocols are important to ensure the supply and sustainability of secretomes for clinical applications. This may eventually impact its commercialization and marketability. In this review, the bioprocessing methods and their impacts on the secretome profile and treatment are discussed. This improves understanding of its fundamental aspects leading to potential clinical applications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

Not applicable.

Abbreviations

Alg:

Alginate

ALI-model:

Acute lung injury mice model

ANGPT1:

Angiopoietin-1

ASC-CCM:

Adipose-derived stem cell concentrated conditioned medium

ASC-S:

Adipose tissue-derived stromal cell secretome

AST-ST:

Hypoxic cultured adipose-derived mesenchymal stem cell secretome

BDNF:

Brain-derived neurotrophic factor

bFGF:

Basic fibroblast growth factor

CG:

Carrageenan

Ch:

Chitosan

CM:

Conditioned media

CNTF:

Ciliary neurotrophic factor

COPD:

Chronic obstructive pulmonary disease

COX2:

Cyclooxygenase 2

CRD:

Chronic respiratory disease

CS:

Chondroitin sulfate

CTGF:

Connective tissue growth factor

CXCL:

C-X-C motif chemokine ligand

DCM:

Dilated cardiomyopathy

dECM:

Cardiac decellularized extracellular matrix

DMEM:

Dulbecco’s modified Eagle’s medium

ECM:

Extracellular matrix

EF-2:

Eukaryotic elongation factor 2

EGF:

Epidermal growth factor

EPO:

Erythropoietin

EPOR:

Erythropoietin receptor

EV:

Extracellular vesicle

FBS:

Fetal bovine serum

FDA:

US Food and Drug Administration

FGF:

Fibroblast growth factor

FLT-3:

Fms-related tyrosine kinase 3

Gal:

Galectin

GDNF:

Glial cell-derived neurotrophic factor

GDNF:

Glial-derived neurotrophic factor

GM-CSF:

Granulocyte-macrophage colony-stimulating factor

GMP:

Good manufacturing practice TGF-β1

HA:

Hyaluronic acid

HGF:

Hepatocyte growth factor

HGF:

Hepatocyte growth factor

HLA-1:

Human leukocyte antigen 1

HLA-G5:

Human leukocyte antigen G5

hNPC:

Human neural precursor cells

HO-1:

Heme oxygenase-1

hPL:

Human platelet lysate

Hypo-CM:

Hypoxic cultured human umbilical cord-derived mesenchymal stem cells secretome

ICAM:

Intercellular adhesion molecule

IDO:

Indoleamine 2,3-dioxygenase

IFN-γ:

Interferon gamma

IGF:

Insulin-like growth factors

IL:

Interleukins

IL18BP:

IL18 binding protein

IL-1Ra:

Interleukin-1 receptor antagonist

iPSC:

Human induced pluripotent stem cell

KGF :

Keratinocyte growth factor

LAP:

Latency-associated protein

LCMS:

Liquid chromatography–mass spectrometry

LCMS:

Liquid chromatography-mass spectrometry

LIF:

Leukemia inhibitory factor

LIGHT:

Tumor necrosis factor superfamily member 14

L-MSC-S:

Limbal mesenchymal stem cell secretome

LSC-Exo:

Lung spheroid cell exosomes

LSC-sec:

Lung spheroid cell secretomes

MCP-1:

Monocyte chemoattractant protein-1

MDK:

Midkine

MMP:

Matrix metalloproteinases

MSC:

Mesenchymal stem cell

MSC-S:

Mesenchymal stem cell–derived secretomes

MWCO:

Molecular weight cut-off

NGF:

Nerve growth factor

NGF:

Nerve growth factor

NO:

Nitric oxide

NT-:

Neurotrophin-

NT-3:

Neurotrophin 3

PBS:

Phosphate buffered saline

PDGF:

Platelet-derived growth factor

PD-L:

Programmed death-ligand

PEDF:

Pigment epithelium-derived factor

PGE2:

Prostaglandin E2

PGF:

Placental growth factor

PNX-canine model:

Pneumonectomy-induced lung injury in a canine model

PVA:

Poly vinyl alcohol

rBMSC:

Rat bone marrow stromal cells

rOBI:

Repetitive ocular blast injury

RV:

Resveratrol

SDF-1:

Stromal cell-derived factor 1

SD-MSC-S:

Skin-derived mesenchymal stem cell secretome

SOD:

Superoxide dismutase

SPH-MYO:

Spheroid-myoblast-conditioned media

STC1:

Stanniocalcin-1

TCA:

Trichloroacetic acid

TF:

Tissue factor

TGF:

Transforming growth factor

TGF-β1:

Transforming growth factor -β1

TIMP:

Metallopeptidase inhibitor

TNF-α:

Tumor necrosis factor alpha

TSG-6:

Tumor necrosis factor stimulated gene 6

VEGF:

Vascularendothelial growth factor

vWF:

vonWillebrand factor

WJ:

Wharton’s jelly

αMEM:

Alpha-minimum essentials medium

References

Download references

Funding

This review is prepared as part of the collaborative work under the Fundamental Research Grant Scheme (FRGS) project funded by the Ministry of Higher Education Malaysia (Project no: DP KPT FRGS/1/2021/SKK06/UM/02/4).

Author information

Authors and Affiliations

Authors

Contributions

Conceptualization: NABNA, WSWKZ and NNR. Drafting and revising: NABNA, VV, WSWKZ, NNR, FN and GJT.

Corresponding author

Correspondence to Wan Safwani Wan Kamarul Zaman.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noor Azlan, N.A.B., Vitus, V., Nor Rashid, N. et al. Human mesenchymal stem cell secretomes: Factors affecting profiling and challenges in clinical application. Cell Tissue Res 395, 227–250 (2024). https://doi.org/10.1007/s00441-023-03857-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00441-023-03857-4

Keywords

Navigation